Medpace Holdings, Inc. $MEDP Shares Acquired by American Century Companies Inc.

American Century Companies Inc. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.7% during the 2nd quarter, Holdings Channel reports. The fund owned 12,717 shares of the company’s stock after purchasing an additional 1,529 shares during the quarter. American Century Companies Inc.’s holdings in Medpace were worth $3,991,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Portside Wealth Group LLC grew its stake in Medpace by 2.5% during the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after purchasing an additional 27 shares in the last quarter. PDS Planning Inc boosted its stake in shares of Medpace by 1.5% in the 2nd quarter. PDS Planning Inc now owns 2,421 shares of the company’s stock valued at $760,000 after buying an additional 35 shares during the period. Benjamin Edwards Inc. grew its position in shares of Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company’s stock worth $366,000 after buying an additional 36 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Finally, Sheets Smith Wealth Management increased its stake in shares of Medpace by 1.3% during the second quarter. Sheets Smith Wealth Management now owns 3,332 shares of the company’s stock worth $1,046,000 after buying an additional 43 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on MEDP shares. Robert W. Baird set a $613.00 price target on shares of Medpace in a research note on Friday, October 24th. Mizuho raised their price objective on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a report on Friday, October 24th. Truist Financial set a $555.00 target price on shares of Medpace in a research note on Monday, October 27th. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and increased their target price for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Finally, Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $487.18.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $549.17 on Tuesday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26. The firm has a market capitalization of $15.47 billion, a P/E ratio of 38.40, a P/E/G ratio of 2.06 and a beta of 1.43. The company’s fifty day moving average price is $568.87 and its 200 day moving average price is $456.62.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter last year, the company posted $3.01 earnings per share. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 668 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares in the company, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 387,925 shares of company stock valued at $233,386,647 in the last three months. 20.30% of the stock is currently owned by company insiders.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.